SARA MESSIER: Open Payments
NPI 1831719566 · SUMTER, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$860 in 48 payments from 11 companies in 2025. Trend: 2023 $16 · 2024 $217 · 2025 $860
Food & beverage: $860
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $225 |
| Teva Pharmaceuticals USA, Inc. | 13 | $224 |
| ABBVIE INC. | 12 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Alkermes, Inc. | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $42 |
| Lundbeck LLC | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: INGREZZA, AUSTEDO XR, VRAYLAR, UZEDY, CAPLYTA, ARISTADA, HETLIOZ, REXULTI.
Industry payments across SC — which companies pay providers there.
